Key Highlights

  • A public offering largely explains why cash and equivalents rose from USD 7.8 million at December 31, 2025 to USD 26.7 million at June 30, 2026.
  • The six months to June 30, 2026 brought a USD 18.0 million net loss, versus USD 23.1 million twelve months prior, and the net operating loss widened to USD 11.3 million.
  • Gross proceeds of USD 22.3 million from the Equity sale, which included the underwriters fully exercising their option, paid for the cash increase.
  • NRx was picked as prime contractor for the SPARC-TMS trial, and the company anticipates USD 11.5 million in non-dilutive DARPA funding once contracting is complete.

Report Timing and the Spending Trend Ahead of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP) is slated to report third quarter 2026 figures on Monday, November 16, 2026, covering the quarter that ended September 30, 2026. The earlier update, issued August 17, 2026, reported a USD 18.0 million net loss across six months and a net operating loss of USD 11.3 million, set against USD 7.6 million in 2025. Attention will fall on commercial launch spending, clinic activity and progress toward first commercial ketamine sales, which the company targets for 2026.

Ketamine Review Outcome and Launch Stock at NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)

The FDA finished the first review cycle of the preservative-free ketamine abbreviated new drug application without major drug-related deficiencies. Only one item, tied to the luer lock on the vial, was flagged, and the maker has filed an attestation covering it. NRx Pharmaceuticals (NASDAQ:NRXP) is aiming for approval and commercial launch in 2026, with 5 million units of launch stock in production and output planned at 1 million units a month. For NRX-100, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) leans on real-world evidence from more than 65,000 patients and targets approval in 2027. Jonathan Javitt, the chief executive, described the second quarter as a major inflection point.

Runway, Financing Sources and Execution Risks at NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)

Management believes that current cash, clinic Revenue growth and the at-the-market program can carry NRx Pharmaceuticals (NASDAQ:NRXP) through at least a year. The larger operating loss stems from Research and Development tied to acquired Assets and heavier selling, general and administrative costs, including hires of key staff and launch-related outlays. Risk areas for NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) include when the FDA acts, Manufacturing work still open, reliance on real-world evidence, how well the commercial launch goes, and dilution from share sales. The USD 11.5 million expected from DARPA will only arrive once the contracting work is finished.

Where Things Stand

Heading into November 16, 2026, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is shifting from a clinical-stage developer into a commercial business. The financial picture rests on USD 26.7 million in cash and a USD 18.0 million net loss over six months, and the net operating loss of USD 11.3 million signals rising launch and staffing outlays. The nearest catalyst is the ketamine application, which the company hopes to see approved in 2026. Next come the NRX-100 filing, aimed at 2027, and the NRX-101 Phase 2 and 3 study backed by DARPA. Investors will look to the third quarter update for clarity on regulatory timing, spending and how long the funded runway lasts.